Half-year report · HY
4574.TEDINET S100YVYD
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥6.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥17m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥41m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥482m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥40m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥11.1bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥12.3bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.7bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.5bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.3bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥66m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥814m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥685m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥142m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥853m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.89 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.51 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.0% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.4% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥433m |
| Infection Control Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥92m |
| Pharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | ¥450m |
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from insurance income ope cf | Prior1InterimDuration | 1000000 | JPY |
| Proceeds from insurance income ope cf | InterimDuration | － | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -17000000 | JPY |
| Income taxes paid ope cf | InterimDuration | -18000000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | 61000000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | -66000000 | JPY |
| Payments into time deposits inv cf | Prior1InterimDuration | － | JPY |
| Payments into time deposits inv cf | InterimDuration | -500000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -148000000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -184000000 | JPY |
| Purchase of intangible assets inv cf | Prior1InterimDuration | -2000000 | JPY |
| Purchase of intangible assets inv cf | InterimDuration | -1000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | 447000000 | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | 295000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -685000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -673000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -673000000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -11000000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -16000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | － | JPY |
| Cash dividends paid fin cf | InterimDuration | -165000000 | JPY |
| Other net fin cf | Prior1InterimDuration | － | JPY |
| Other net fin cf | InterimDuration | 0 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -684000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -853000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -65000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 15000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -392000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -1589000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4532000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4256000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 4139000000 | JPY |
| Cash and cash equivalents | InterimInstant | 2666000000 | JPY |
| Advertising expenses sga | Prior1InterimDuration | 183000000 | JPY |
| Advertising expenses sga | InterimDuration | 190000000 | JPY |
| Payroll and allowances sga | Prior1InterimDuration | 350000000 | JPY |
| Payroll and allowances sga | InterimDuration | 360000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 28000000 | JPY |
| Provision for bonuses sga | InterimDuration | 68000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 32000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 30000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2206000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 2412000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 2412000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |